Health systems are facing hurdles to implementing new and effective metastatic urothelial carcinoma (mUC) therapies into ...

Opdualag – which combines the PD-1 inhibitor nivolumab in BMS' blockbuster cancer drug Opdivo with LAG-3 inhibitor relatlimab ...

Disease control rate (DCR) of 78% (7 of 9) in combination escalation arm of MDNA11 with Merck’s (known as MSD outside of Canada and the US) ...

Patients receiving an immune checkpoint inhibitor for a neoplasm face an increased risk for rheumatoid arthritis, an observational study found.

Dr. Guru P Sonpavde discusses updated data from studies like EV-302 and CheckMate 274 for patients with urothelial cancer at ...

Dr Scott Tagawa discusses how dose adjustments can optimize the use of enfortumab vedotin in urothelial cancer.

Report on how AI is driving market transformation - The elderberry market and it is set to grow by USD 349.5 million from ...

Institutional investors advised by J.P. Morgan Asset Management in partnership with the principals of Georgia Capital, an Atlanta-based residential investment and development firm, and its affiliated ...

NEW YORK - Pfizer Inc. (NYSE: NYSE:PFE), a pharmaceutical giant with a market capitalization of $17.4 billion, has announced results from its Phase 3 TALAPRO-2 study which show that a combination of ...

Biologic medicines have transformed treatment for numerous chronic and life-threatening conditions such as cancer, ...

President Trump's nominee, Robert F. Kennedy Jr., is the right person to lead Health and Human Services to transform the ...

AEMD READ THE FULL AEMD RESEARCH REPORT Patient treatments begin in AEMD’s basket oncology trial, enrollments expected to accelerate Aethlon Medical (NASDAQ:AEMD) reported FY 3Q results yesterday and ...